Deze vertaling wordt voorbereid. Voorlopig tonen we de oorspronkelijke Engelse versie.
Regelgeving en recht · 2-11-20231 min lezen
Prospective Grant of an Exclusive Patent License: Mutant IDH1 Inhibitors Useful for Treating Cancer
Lokale automatische vertaling · Oorspronkelijke brontaal
Samenvatting
The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Platform Pharmaceuticals, Inc. ("Platform Pharma"), headquartered in New York, NY.
Oorspronkelijke brontaal: Federal Register — All DocumentsOrigineel bericht openen →